Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR. Gadi D, et al. Among authors: lederer ja. Leukemia. 2022 Mar;36(3):723-732. doi: 10.1038/s41375-021-01441-9. Epub 2021 Nov 6. Leukemia. 2022. PMID: 34743191 Free PMC article. Clinical Trial.
Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
Koch MS, Zdioruk M, Nowicki MO, Griffith AM, Aguilar E, Aguilar LK, Guzik BW, Barone F, Tak PP, Tabatabai G, Lederer JA, Chiocca EA, Lawler S. Koch MS, et al. Among authors: lederer ja. J Immunother Cancer. 2022 Jan;10(1):e003368. doi: 10.1136/jitc-2021-003368. J Immunother Cancer. 2022. PMID: 35017150 Free PMC article.
Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma.
Koch MS, Zdioruk M, Nowicki MO, Griffith AM, Aguilar-Cordova E, Aguilar LK, Guzik BW, Barone F, Tak PP, Schregel K, Hoetker MS, Lederer JA, Chiocca EA, Tabatabai G, Lawler SE. Koch MS, et al. Among authors: lederer ja. Mol Ther Oncolytics. 2022 Jul 31;26:275-288. doi: 10.1016/j.omto.2022.07.009. eCollection 2022 Sep 15. Mol Ther Oncolytics. 2022. PMID: 36032633 Free PMC article.
Stability of Th1 and Th2 populations.
Perez VL, Lederer JA, Lichtman AH, Abbas AK. Perez VL, et al. Among authors: lederer ja. Int Immunol. 1995 May;7(5):869-75. doi: 10.1093/intimm/7.5.869. Int Immunol. 1995. PMID: 7547713
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders.
Zhou L, Zeng Z, Egloff AM, Zhang F, Guo F, Campbell KM, Du P, Fu J, Zolkind P, Ma X, Zhang Z, Zhang Y, Wang X, Gu S, Riley R, Nakahori Y, Keegan J, Haddad R, Schoenfeld JD, Griffith O, Manguso RT, Lederer JA, Liu XS, Uppaluri R. Zhou L, et al. Among authors: lederer ja. J Immunother Cancer. 2022 Jan;10(1):e004034. doi: 10.1136/jitc-2021-004034. J Immunother Cancer. 2022. PMID: 35058328 Free PMC article.
B cells.
MacConmara M, Lederer JA. MacConmara M, et al. Among authors: lederer ja. Crit Care Med. 2005 Dec;33(12 Suppl):S514-6. doi: 10.1097/01.ccm.0000190616.15952.4b. Crit Care Med. 2005. PMID: 16340437 Review. No abstract available.
164 results